Randomised, Phase I fMRI study (n=128) comparing a single infusion of AZD6765, ketamine, and placebo in adults with depression to assess BOLD fMRI responses.
This randomized study compares the pharmacological effects of a single infusion of AZD6765 versus ketamine and placebo on BOLD signal measured with fMRI in adults with major depressive disorder.
Primary purpose is basic science; three single-infusion arms (AZD6765, ketamine, placebo). Outcomes include fMRI BOLD responses and safety/tolerability measures; sites in Manchester and Oxford, UK.
Single infusion of investigational NMDA antagonist (AZD6765).
AZD6765 single infusion (dose not specified in registry); experimental agent recorded as AZD6765.
Single infusion of ketamine comparator.
Single infusion of ketamine (dose not specified in registry).
Single placebo infusion.
Placebo infusion.